ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE and ECONOMIC PROBLEM

Overview

ECONOMIC PROBLEM is the #17 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc.. There are 680 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE to ECONOMIC PROBLEM. This represents approximately 1.5% of all 45,551 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE who experience economic problem should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

ECONOMIC PROBLEM is a less commonly reported adverse event for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, but still significant enough to appear in the safety profile.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE

In addition to economic problem, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE:

• BONE DENSITY DECREASED — 4,550 reports
• RENAL INJURY — 3,304 reports
• SKELETAL INJURY — 3,020 reports
• CHRONIC KIDNEY DISEASE — 2,482 reports
• TOOTH LOSS — 2,455 reports
• BONE LOSS — 2,134 reports
• OSTEONECROSIS — 2,095 reports
• RENAL FAILURE — 2,052 reports
• TOOTH INJURY — 1,970 reports
• MULTIPLE FRACTURES — 1,957 reports

Other Drugs Associated with ECONOMIC PROBLEM

The following drugs have also been linked to economic problem in FDA adverse event reports:

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE cause ECONOMIC PROBLEM?

ECONOMIC PROBLEM has been reported as an adverse event in 680 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is ECONOMIC PROBLEM with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE?

ECONOMIC PROBLEM accounts for approximately 1.5% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.

What should I do if I experience ECONOMIC PROBLEM while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE?

If you experience economic problem while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages